| abstract |
Novel compositions and methods are provided for the treatment of cancer employing monoclonal antibodies (MoAbs) conjugated to a toxin. According to the present invention, MoAbs defining epitopes on either a tumor associated glycoprotein antigen of about 72 kD m.w. or on carcinoembryonic antigen conjugated to a ribosomal inhibiting protein, or the like, are employed either alone or in combination as cytotoxic agents in the treatment of various cancers including, but not limited to, colorectal carcinoma, ovarian carcinoma and osteogenic sarcoma. n Hydridomas XMMCO-791 and XMMCO-228 were deposited with the A.T.C.C. on August 14, 1986 and given A.T.C.C. Accession Nos. HB 9173 and HB 9174, respectively. |